Kornimate/medical-research-clean huggingface dataset:
polyglactin sutures versus nylon sutures for suturing of conjunctival autograft in pterygium surgery: a randomised controlled trial

Conditions: Pterygium

Summary: to compare the use of polyglactin sutures versus nylon sutures for conjunctival autograft suturing in pterygium surgery.


Eligibility criteria:
inclusion criteria: * inclusion criteria included patients with primary nasal pterygium, aged 18 years or older, and able to cooperate surgery under local anaesthesia. exclusion criteria: * patients with recurrent pterygium, scarred superior conjunctiva, previous surgery involving the superior bulbar conjunctiva, history of glaucoma, and cicatricial ocular surface disease were excluded
reflux in spinal cord injury patients with neurogenic lower urinary tract dysfunction

Conditions: Vesico-ureteral Reflux; Spinal Cord Injury

Summary: the purpose of this study is to investigate the incidence of reflux in patients with spinal cord injury in relation to the lesion level, duration of injury and bladder management

vesico-ureteral reflux was the main cause for renal failure and reduced life expectancy in patients with neurogenic bladder dysfunction due to spinal cord injury. neurogenic detrusor overactivity leads to high intravesical pressure and may induce reflux. decreasing intravesical pressure and increasing bladder capacity is necessary to prevent reflux and secondary renal failure.

Eligibility criteria:
inclusion criteria: * spinal cord injury * neurogenic lower urinary tract dysfunction * written informed consent exclusion criteria: * lower urinary tract dysfunction due to other causes than spinal cord injury

Keywords: vesico-ureteral reflux neurogenic bladder dysfunction spinal cord injury
pharmaceutical intervention and adherence to bdmards in spondyloarthritis.

Conditions: Spondyloarthritis; Treatment Adherence

Summary: there is a lack of knowledge among patients concerning their treatment with bdmards, which could lead to low adherence. the objective of this study is to assess the impact of a pharmacist's intervention on the adherence to bdmards in patients with spondyloarthritis.

this is an interventional, controlled, open-label and monocentric study. 80 patients are planned to be included. after written informed consent will be obtained, the patients will be randomized in two arms: * intervention arm: intervention of a pharmacist who will explain bdmards management. * control arm, without intervention. two primary end-points are defined: 1. the changes from baseline to m6 in the patients' knowledge score about subcutaneous bdmard management 2. the changes from baseline to m6 in medication possession ratio (mpr) as secondary end-points, the changes in disease activity and patients' satisfaction regarding the pharmacists' intervention are evaluated.

Eligibility criteria:
inclusion criteria: * outpatients from rheumatology department at cochin hospital * diagnosis of spondyloarthritis * under treatment with subcutaneous bdmards for at least 6 months * disease activity stable for at least 6 months * no treatment modification 3 months before or after inclusion in the study * informed consent signed and dated * older than 18 years * patients who speak french exclusion criteria: * patients who have had a change in the treatment of spa during the 3 months prior or after the inclusion * history of psychological problems * patients who need other persons to manage their treatment.

Keywords: treatment knowledge
colorectal polyp discrimination using high-definition narrow band imaging

Conditions: Colon Polyps

Summary: the investigators seek to compare the accuracy of the existing colonoscope model to determine the magnitude of the improvement the investigators can expect in polyp discrimination as neoplastic or non-neoplastic.

information will be collected. images will be taken.

Eligibility criteria:
inclusion criteria: * age 18 and older * presenting for surveillance, screening or diagnostic colonoscopy * willingness to provide informed consent exclusion criteria: * inability to provided informed consent * pregnancy * known inflammatory bowel disease * personal or family history of polyposis or nonpolyposis syndrome * emergency colonoscopy/endoscopy * coagulopathy or thrombocytopenia preventing polypectomy * procedure indication for acute bleeding or active colitis

Keywords: colonoscopy colon polyps
potential drug interaction between alxn2040 and rosuvastatin

Conditions: Healthy Participants

Summary: this study will assess the potential drug-drug interaction (ddi) between alxn2040 and rosuvastatin.

this is an open-label, 2-treatment, 2-period, fixed-sequence ddi study in healthy adult participants. this study will comprise of: * screening duration of 27 days. * two treatment periods: approximately 14 days. treatment period 1: 6 days treatment period 2: 8 days * follow-up: 7 (± 2) days following the final dose of study intervention. there will be a washout period of at least 5 days between the single dose of rosuvastatin in treatment period 1 and the first dose of alxn2040 in treatment period 2. each participant will be involved in the study for approximately 48 days.

Eligibility criteria:
inclusion criteria: * medically healthy participants with no clinically significant or relevant abnormalities as determined by medical history, physical examination, vital signs, 12-lead electrocardiogram (ecg), and clinical laboratory safety evaluation (hematology, biochemistry, coagulation, and urinalysis) that is reasonably likely to interfere with participation in or ability to complete the study, or to potentially confound interpretation of study results, as assessed by the investigator. * body mass index (bmi) within the range 18 to 32 kg/m\^2 (inclusive), with a minimum body weight of 50.0 kg at screening. exclusion criteria: * history of any medical or psychiatric condition or disease that, in the opinion of the investigator, might limit the participant's ability to complete or participate in this clinical study, confound the results of the study, or pose an additional risk to the participant by their participation in the study. * history of meningococcal infection. * history of drug or alcohol abuse within 2 years prior to first dose of study intervention, or positive drugs-of-abuse or alcohol screen at screening or day -1. * current tobacco users or smokers or a positive cotinine test at screening. * any major surgery within 8 weeks of screening. * donation of whole blood from 3 months prior to first dose, or of plasma from 30 days prior to first dose of study intervention. * history of malignancy within 5 years prior to screening. * evidence of human immunodeficiency virus (hiv) infection (hiv antibody positive) at screening. * evidence of hepatitis b (positive hepatitis b surface antigen or positive core antibody with negative surface antibody) or hepatitis c viral infection (hepatitis c virus antibody positive) at screening. * female participant who is pregnant, breastfeeding, or intending to conceive during the course of the study.

Keywords: drug-drug interaction breast cancer resistance protein organic-anion transporting polyprotein
exercise therapy program in ankylosing spondylitis patients

Conditions: Ankylosing Spondylitis

Summary: mobility exercises are used in ankylosing spondylitis (as) patients to preserve and restore axial mobility, but there are no data regarding a specific rehabilitation program that includes flexibility alone and its association with resistance exercises in as patients with stable disease activity. so, we assessed the effects of two exercise programs in terms of mobility, functional capacity, quality of life and disease activity in as patients. methods. fifty-five sedentary as patients with a bath ankylosing spondylitis activity index (basdai) \<4 were included.

the as patients were randomly assigned into three groups, to receive a mobility exercise program (m) or mobility plus elastic resistance exercise program (m+r) or no exercise (c). the exercises group sessions were conducted twice per week for 16 weeks. this supervised program comprised 30 minutes of outdoor stretching and mobility exercises for the spine and limbs (m). after the flexibility program, m+r group carry out more 30 minutes of elastic resistance exercises. the mobility, disease activity and functional parameters were evaluated at baseline and after 16 weeks, with the evaluator blinded to the treatment group.

Eligibility criteria:
inclusion criteria: * ankylosing spondylitis patient * basdai index lower than 4 * physical inactive * functional class i to iii exclusion criteria: * fibromyalgia * cardiovascular disease * pain visual analogue scale ("vas") over 8

Keywords: exercise mobility strengthening physiotherapy
antimicrobial resistance in cirrhotic patients

Conditions: Cirrhosis

Summary: cirrhotic patients are more vulnerable to bacterial infection, and infection is one of the most common causes of acute liver disease decompensation.

cirrhotic patients are more vulnerable to bacterial infection which is a common cause of acute liver disease decompensation. the aim of this study will characterize the antimicrobial resistance and distribution of bacteria isolated from chronic hepatic patients with pulmonary infections, as well as to evaluate the antimicrobial susceptibility of bacteria isolated from sputum.

Eligibility criteria:
inclusion criteria: 1. adults' older than 18 years with clinical evidence of liver disease exclusion criteria: 1. pregnancy 2. intensive care unite stay of more than 24 hours 3. malignancy 4. organ transplantation 5. acquired immune deficiency syndrome
intrepid - iray plus anti-vegf treatment for patients with wet amd

Conditions: AMD; Wet AMD; Age-Related Macular Degeneration; Wet Age-Related Macular Degeneration; Macular Degeneration; Eye Diseases; Retinal Diseases

Summary: the purpose of this study is to confirm the safety and establish the effectiveness of two doses from the iray system for the treatment of wet amd.

the purpose of this study is to confirm the safety of low voltage external beam radiotherapy using the iray system at two dose levels for the treatment of cnv secondary to neovascular amd and to determine if the iray system is effective in sparing the number of lucentis injections during the first 12 months.

Eligibility criteria:
inclusion criteria: * patients must have neovascular amd diagnosed within the previous 3 years, have received at least 3 injections with lucentis® or avastin® within the previous year and have the need for treatment with anti-vegf therapy due to increased fluid or persistent cysts on oct, or leakage on fa. * patients must have a total lesion size of \<12 disc areas and a cnv lesion with the greatest linear dimension of \<6 mm, but not greater than 3 mm from the center of the fovea to the furthest point on the lesion perimeter. * the distance from the center of the fovea to the nearest edge of the optic disc should be not less than 3 mm. * patients must patient must be at least 50 years of age. * women must be post-menopausal ≥1 year or surgically sterilized, or a pregnancy screen must be performed prior to the study and a reliable form of contraception approved by the investigator must be maintained during the study. * patient must have best corrected visual acuity of 75 to 25 letters in the study eye and at least 20 letters in the fellow eye. exclusion criteria: * cnv due to causes other than amd, including ocular histoplasmosis syndrome, angioid streaks, multifocal choroiditis, choroidal rupture, or pathologic myopia (spherical equivalent ≥ -8 diopters). * an axial length of ≤20 mm or ≥26 mm. * previously diagnosed with diabetes mellitus and/or an hba1c of \>6.5%, and with retinal findings consistent with diabetic retinopathy. * prior or concurrent therapies for age related macular degeneration including submacular surgery, subfoveal thermal laser photocoagulation (with or without photographic evidence), transpupillary thermotherapy (ttt), ocular photodynamic therapy, radiation therapy to the head or neck in the study eye. * previous posterior vitrectomy, or any surgery in the study eye within 6 months or yag capsulotomy within 3 months prior to the screening visit.

Keywords: oraya oraya therapeutics, inc. low voltage stereotactic radiotherapy radiotherapy iray ranibizumab lucentis amd macular degeneration xray radiation x ray external beam radiation radiosurgery
relationships between exercise and appetite in women with loss of control eating

Conditions: Eating Disorders; Binge-Eating Disorder; Bulimia Nervosa

Summary: this pilot study is a first step in looking at the relationship between exercise and appetite in women with loss of control eating.


Eligibility criteria:
inclusion criteria: * engage in loss of control eating at least 12 times in the last three months * clinically significant eating disorder-related impairment (cia \&gt; 15) * taking hormonal contraception * minimum vo2max of 50th percentile for age and sex assigned at birth * be willing to eat study-provided foods * likes chocolate (at least 6/10 on 10 point scale) exclusion criteria: * bmi \&lt; 18.5 kgm/2 * medical conditions that affect appetite or weight (e.g., diabetes mellitus, thyroid disease) * recent pregnancy or breastfeeding (prior 6 months) * relevant food allergies (e.g., wheat, chocolate) * specific phobia, blood-injection-injury type * medical condition that precludes safe participation in exercise (e.g., stress fracture) * medications that acutely affect appetite (e.g., glp-1 agonists; psychiatric medications allowed)

Keywords: exercise eating disorders
efficacy and safety study of seroquel sr in the treatment of major depressive disorder

Conditions: Major Depressive Disorder

Summary: the primary purpose of this study is to evaluate whether treatment with (seroquel sr) quetiapine fumarate sustained release (sr) for 9 weeks compared to placebo will improve depressive symptoms in elderly patients with major depressive disorder. please note: seroquel sr and seroquel xr refer to the same formulation. the sr designation was changed to xr after consultation with fda.


Eligibility criteria:
inclusion criteria: * male or female patients, 66 years or older, with a documented clinical diagnosis of mdd. exclusion criteria: * the presence of dementia or mental disorder other than mdd within 6 months of enrolment, * uncontrolled hypertension, substance or alcohol abuse * a current diagnosis of cancer or a current or past diagnosis of stroke

Keywords: major depressive disorder mdd
gait, stair climbing and postural stability in knee osteoarthritis patients after hyaluronic acid injection

Conditions: Bilateral Knee Osteoarthritis

Summary: treatment: five intro-articular hyaluronic acid injection assessment has two parts, that are as follow: 1. postural stability and risk of fall assessment using biodex stability index and "timed up and go" test 2. gait and stair climbing assessment using vicon motion capture system synchronized with four force plates. for knee oa subjects, assessment was done in week one or before injection; and for healthy controls one assessment was performed.

this study aimed to assess the effect of hyaluronic acid injection on postural stability, biomechanics of gait and stair climbing in individuals with bilateral knee osteoarthritis (oa). participants were individuals with knee oa (control and treatment) and healthy people.

Eligibility criteria:
inclusion criteria: * mild and moderate bilateral knee osteoarthritis * age between 50 and 70 years exclusion criteria: * recent lower limb injury * diabetic * knee or hip replacement * knees ha injection in last 6 months * any neuromuscular disease such as stroke and parkinson
evaluation of atherosclerotic plaques in abdominal ct studies

Conditions: Prostatic Neoplasms

Summary: background: fat and calcium can build up as plaque in artery walls. the agatston score measures plaque using computed tomography (ct) that does not use an injected contrast agent. plaque in the arteries of the pelvis and abdomen is linked to cardiovascular disease (cvd) risk factors. it also may affect cancer. but abdominal cts use a contrast agent (cect). therefore, the agatston score cannot be used. researchers want to find a way to measure plaque in cects. this will help them use abdominal cts to measure plaque without extra radiation. objective: to measure atherosclerotic plaques on cect in a group of males. eligibility: men ages 30-90 with prostate cancer (proven with biopsies) who have abdomen ct studies in the pacs (picture archiving system) in the clinical center. also, men or women of all ages who have multiphase abdomen and pelvic ct studies that are in the pacs. design: this study will use data gathered since 1/1/2013. data will also be taken from protocol 03-cc-0128 and clinical trials 15-c-0124, 16-c-0048, 14-c-0112, and 04-c-0274. participants from these studies have allowed their samples to be used in the future. participants will be found via keyword searches on nih databases. their ct and mri scans will be used. data such as age, race, disease, and treatment will be used. results of other tests may be used. the plaque in participants abdomen and iliac arteries will be measured. it will be compared with biomarkers related to cvd and prostate cancer, such as weight, age, and race. this study will take place at one site. data will be stored on secure computers. printouts will be kept in locked rooms.

evaluation of atherosclerotic plaques in prostate cancer patients. study description: this study measures atherosclerotic plaques in the vessels of prostate cancer patients in contrast-enhanced computed tomography (cect), then finds correlation between the plaque and clinical biomarkers. these biomarkers include laboratory tests, pathologic findings, underlying risk factors, demographic information, and outcomes of the patient. objectives: primary objective: measure atherosclerotic plaques on contrast-enhanced computed tomography (cect). secondary objective: find correlation between plaque measurement and clinical biomarkers of prostate cancer patients. study population: up to 1,000 nih clinical center patients. description of sites/facilities conducting research: nih clinical center study duration: 10 years

Eligibility criteria:
* inclusion criteria: the study will use existing radiologic data. exclusion criteria: none

Keywords: ct measurement cvd ct coronary angiogram clinical biomarkers natural history
eye scanning for safety driving

Conditions: Dementia; Mild Cognitive Impairment; Older Adults

Summary: this is an experimental study protocol to investigate the use of vision-based assessments like eye-tracking and visual processing tests to evaluate driving ability in older adults with and without dementia. the study aims to address the research gap on the specific eye movement patterns and visual behaviors of individuals with alzheimer\&#39;s disease during high-risk driving scenarios. the study will recruit 15 participants aged 65+ with cognitive impairment and 15 without cognitive impairment. their cognitive status will be assessed using the mini-mental state exam (mmse) and hopkins verbal learning test (hvlt). participants will undergo visual screening tests like visual sensitivity, eye movement scanning, and the corsi block span test. their driving performance will be evaluated through a hazard perception test and driving experience survey. statistical analyses like correlations, group comparisons, regression, and mediation analyses will be conducted to examine the relationships between cognitive status, visual screening scores, and driving performance scores. the goal is to determine if visual measures can predict driving ability and mediate the link between cognitive function and driving performance in those with dementia. in summary, it is a protocol for an observational study using vision-based techniques to assess driving capacity in older adults, especially those with alzheimer\&#39;s disease or dementia.


Eligibility criteria:
inclusion criteria: * participants with cognitive impairment aged 65 and/or older and older adults without cognitive impairment will be recruited for this study. exclusion criteria: * participants with other neurological disease (stroke, parkinson's, or multiple sclerosis), * psychiatric conditions (depression, anxiety disorder, etc.) and a history of severe psychiatric disorders (schizoaffective/bipolar disorders, or schizophrenia), * severe vision/hearing impairments that cannot be corrected with aids, * unable to comprehend questionnaire material study procedures and give consent.
the effects of relaxation techniques on pain, fatigue and kinesiophobia in multiple sclerosis patients: a three arms randomized trial

Conditions: Multiple Sclerosis, Relapsing-Remitting; Pain, Chronic; Fatigue Syndrome, Chronic; Kinesiophobia

Summary: even though, current treatments including ivig, corticosteroids, biological agents can provide positive effects on ms symptoms, ms cannot be cured completely today. therefore, in addition to the available medical treatment options, patients may tend towards complementary and integrative therapies. relaxation techniques are one of the non-pharmacological and side-effect-free therapy options that are currently used to alleviate the symptoms of many different chronic diseases. progressive muscle relaxation exercise (pmr) and benson relaxation technique (brt) are two common types of relaxation techniques recommended for symptom management in chronic diseases owing to simple to learn and apply compared to other complementary and integrative methods for patients. pmr is uncomplicated and low-cost method, originally designed by jacobson (1938), which helps individuals to feel calmer through consecutive muscle tension and relaxation of a muscle group. this method can relieve muscle tension, facilitate sleep, and reduce severity of pain and fatigue. there are studies in the literature reporting the positive effects of pmr on fatigue, sleep quality, quality of life, anxiety and stress in ms patients. one of these techniques which is well tolerated is brt, designed by herbert benson in the 1970s as a nonpharmacologic and behavioral method. this technique led to relaxation using mental imagery and mediation. brt creates a relaxation influence in the body by decreasing the sympathetic nervous system activity and increasing the parasympathetic nervous system activity. there are few studies in the literature reporting that brt is beneficial on pain and fatigue in ms patients.to the best of our knowledge, there is no study on the impact of relaxation techniques on pain, fatigue and kinesophobia in ms patients. the aim of this study was to examine and compare the effects of pmr and brt on abovementioned symptoms in ms patients.


Eligibility criteria:
inclusion criteria: * over the age of 18 * having relapsing-remitting ms type and not had an attack during the study * not receiving any other complementary and integrative therapy during the research, * with an expanded disability status scale score of 5.5 and below, * volunteer to participate in study exclusion criteria: * having physical or mental health problems that can interfere with communication * having heart failure, copd, asthma disease, renal failure, musculoskeletal problem such as fracture, plaster cast, amputation, fibromyalgia, ankylosing spondylitis, rheumatoid arthritis, deep anemia (hmg \<8 mg / dl) or oncological diagnoses * not having undergone any surgical operation in the last 3 months

Keywords: multiple sclerosis pain fatigue kinesiophobia relaxation techniques muscle relaxation